295 related articles for article (PubMed ID: 29733695)
1. Can Apparent Diffusion Coefficient Values Assist PI-RADS Version 2 DWI Scoring? A Correlation Study Using the PI-RADSv2 and International Society of Urological Pathology Systems.
Gaur S; Harmon S; Rosenblum L; Greer MD; Mehralivand S; Coskun M; Merino MJ; Wood BJ; Shih JH; Pinto PA; Choyke PL; Turkbey B
AJR Am J Roentgenol; 2018 Jul; 211(1):W33-W41. PubMed ID: 29733695
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Prostate Imaging Reporting and Data System versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.
Krishna S; McInnes M; Lim C; Lim R; Hakim SW; Flood TA; Schieda N
AJR Am J Roentgenol; 2017 Dec; 209(6):W365-W373. PubMed ID: 28981356
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic performance and reproducibility of T2w based and diffusion weighted imaging (DWI) based PI-RADSv2 lexicon descriptors for prostate MRI.
Benndorf M; Hahn F; Krönig M; Jilg CA; Krauss T; Langer M; Dovi-Akué P
Eur J Radiol; 2017 Aug; 93():9-15. PubMed ID: 28668436
[TBL] [Abstract][Full Text] [Related]
4. Intraductal carcinoma of the prostate (IDC-P) lowers apparent diffusion coefficient (ADC) values among intermediate risk prostate cancers.
Currin S; Flood TA; Krishna S; Ansari A; McInnes MDF; Schieda N
J Magn Reson Imaging; 2019 Jul; 50(1):279-287. PubMed ID: 30585372
[TBL] [Abstract][Full Text] [Related]
5. Predictive role of PI-RADSv2 and ADC parameters in differentiating Gleason pattern 3 + 4 and 4 + 3 prostate cancer.
Alessandrino F; Taghipour M; Hassanzadeh E; Ziaei A; Vangel M; Fedorov A; Tempany CM; Fennessy FM
Abdom Radiol (NY); 2019 Jan; 44(1):279-285. PubMed ID: 30066169
[TBL] [Abstract][Full Text] [Related]
6. Effect of observation size and apparent diffusion coefficient (ADC) value in PI-RADS v2.1 assessment category 4 and 5 observations compared to adverse pathological outcomes.
Abreu-Gomez J; Walker D; Alotaibi T; McInnes MDF; Flood TA; Schieda N
Eur Radiol; 2020 Aug; 30(8):4251-4261. PubMed ID: 32211965
[TBL] [Abstract][Full Text] [Related]
7. Prospective comparison of PI-RADS version 2 and qualitative in-house categorization system in detection of prostate cancer.
Gaur S; Harmon S; Mehralivand S; Bednarova S; Calio BP; Sugano D; Sidana A; Merino MJ; Pinto PA; Wood BJ; Shih JH; Choyke PL; Turkbey B
J Magn Reson Imaging; 2018 Nov; 48(5):1326-1335. PubMed ID: 29603833
[TBL] [Abstract][Full Text] [Related]
8. PI-RADS version 2: quantitative analysis aids reliable interpretation of diffusion-weighted imaging for prostate cancer.
Park SY; Shin SJ; Jung DC; Cho NH; Choi YD; Rha KH; Hong SJ; Oh YT
Eur Radiol; 2017 Jul; 27(7):2776-2783. PubMed ID: 27957637
[TBL] [Abstract][Full Text] [Related]
9. The performance of PI-RADSv2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer.
Nougaret S; Robertson N; Golia Pernicka J; Molinari N; Hötker AM; Ehdaie B; Sala E; Hricak H; Vargas HA
Abdom Radiol (NY); 2017 Jul; 42(7):1968-1974. PubMed ID: 28258355
[TBL] [Abstract][Full Text] [Related]
10. Prospective Inclusion of Apparent Diffusion Coefficients in Multiparametric Prostate MRI Structured Reports: Discrimination of Clinically Insignificant and Significant Cancers.
Costa DN; Xi Y; Aziz M; Passoni N; Shakir N; Goldberg K; Francis F; Roehrborn CG; Leon AD; Pedrosa I
AJR Am J Roentgenol; 2019 Jan; 212(1):109-116. PubMed ID: 30383404
[TBL] [Abstract][Full Text] [Related]
11. Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison.
Tosun M; Uslu H
Clin Imaging; 2021 Oct; 78():98-103. PubMed ID: 33773450
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
13. Intra- and interreader reproducibility of PI-RADSv2: A multireader study.
Smith CP; Harmon SA; Barrett T; Bittencourt LK; Law YM; Shebel H; An JY; Czarniecki M; Mehralivand S; Coskun M; Wood BJ; Pinto PA; Shih JH; Choyke PL; Turkbey B
J Magn Reson Imaging; 2019 Jun; 49(6):1694-1703. PubMed ID: 30575184
[TBL] [Abstract][Full Text] [Related]
14. Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary?
Felker ER; Raman SS; Margolis DJ; Lu DSK; Shaheen N; Natarajan S; Sharma D; Huang J; Dorey F; Marks LS
AJR Am J Roentgenol; 2017 Dec; 209(6):1272-1277. PubMed ID: 28858541
[TBL] [Abstract][Full Text] [Related]
15. Effects of the addition of quantitative apparent diffusion coefficient data on the diagnostic performance of the PI-RADS v2 scoring system to detect clinically significant prostate cancer.
Moraes MO; Roman DHH; Copetti J; de S Santos F; Agra A; Noronha JAP; Carvalhal G; Neto EJD; Zanon M; Baldisserotto M; Hochhegger B
World J Urol; 2020 Apr; 38(4):981-991. PubMed ID: 31175458
[TBL] [Abstract][Full Text] [Related]
16. Peripheral zone lesions of intermediary risk in multiparametric prostate MRI: Frequency and validation of the PI-RADSv2 risk stratification algorithm based on focal contrast enhancement.
Benndorf M; Waibel L; Krönig M; Jilg CA; Langer M; Krauss T
Eur J Radiol; 2018 Feb; 99():62-67. PubMed ID: 29362152
[TBL] [Abstract][Full Text] [Related]
17. Comparison of PI-RADS 2, ADC histogram-derived parameters, and their combination for the diagnosis of peripheral zone prostate cancer.
Lin WC; Westphalen AC; Silva GE; Chodraui Filho S; Reis RB; Muglia VF
Abdom Radiol (NY); 2016 Nov; 41(11):2209-2217. PubMed ID: 27364781
[TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant prostate cancer in patients with elevated PSA.
De Visschere P; Lumen N; Ost P; Decaestecker K; Pattyn E; Villeirs G
Clin Radiol; 2017 Jan; 72(1):23-32. PubMed ID: 27726850
[TBL] [Abstract][Full Text] [Related]
19. A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI).
Gaur S; Harmon S; Gupta RT; Margolis DJ; Lay N; Mehralivand S; Merino MJ; Wood BJ; Pinto PA; Shih JH; Choyke PL; Turkbey B
Acad Radiol; 2019 Jan; 26(1):5-14. PubMed ID: 29705281
[TBL] [Abstract][Full Text] [Related]
20. Comparison of quantitative apparent diffusion coefficient parameters with prostate imaging reporting and data system V2 assessment for detection of clinically significant peripheral zone prostate cancer.
Hassanzadeh E; Alessandrino F; Olubiyi OI; Glazer DI; Mulkern RV; Fedorov A; Tempany CM; Fennessy FM
Abdom Radiol (NY); 2018 May; 43(5):1237-1244. PubMed ID: 28840280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
